At the time of writing, Keros Therapeutics Inc [KROS] stock is trading at $11.03, up 3.96%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KROS shares have gain 8.14% over the last week, with a monthly amount drifted -3.33%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Keros Therapeutics Inc [NASDAQ: KROS] stock has seen the most recent analyst activity on January 21, 2025, when Cantor Fitzgerald downgraded its rating to a Neutral. Previously, Wedbush downgraded its rating to Neutral on January 17, 2025, and kept the price target unchanged to $15. On December 16, 2024, Oppenheimer reiterated its Outperform rating and revised its price target to $63 on the stock. Guggenheim downgraded its rating to a Neutral. H.C. Wainwright reiterated its recommendation of a Buy and reduced its price target to $47 on December 13, 2024. William Blair downgraded its rating to Mkt Perform for this stock on December 12, 2024. In a note dated December 12, 2024, TD Cowen downgraded an Hold rating on this stock.
For the past year, the stock price of Keros Therapeutics Inc fluctuated between $9.77 and $73.00. Currently, Wall Street analysts expect the stock to reach $101 within the next 12 months. Keros Therapeutics Inc [NASDAQ: KROS] shares were valued at $11.03 at the most recent close of the market. An investor can expect a potential return of 815.68% based on the average KROS price forecast.
Analyzing the KROS fundamentals
According to Keros Therapeutics Inc [NASDAQ:KROS], the company’s sales were 0.65M for trailing twelve months, which represents an 4750.00% jump. Gross Profit Margin for this corporation currently stands at -0.27% with Operating Profit Margin at -313.42%, Pretax Profit Margin comes in at -278.91%, and Net Profit Margin reading is -278.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.42 and Total Capital is -0.37. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.71 points at the first support level, and at 10.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.23, and for the 2nd resistance point, it is at 11.44.
Ratios To Look Out For
It is important to note that Keros Therapeutics Inc [NASDAQ:KROS] has a current ratio of 19.03. Also, the Quick Ratio is 19.03, while the Cash Ratio stands at 18.3. Considering the valuation of this stock, the price to sales ratio is 687.37, the price to book ratio is 0.81.
Transactions by insiders
Recent insider trading involved GORDON CARL L, Director, that happened on Aug 13 ’24 when 0.25 million shares were sold. Director, ORBIMED ADVISORS LLC completed a deal on Aug 13 ’24 to sell 0.25 million shares. Meanwhile, Shareholder OrbiMed Genesis Master Fund, L bought 29400.0 shares on Aug 13 ’24.
